Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(52 sites)
United States
City of Hope, Duarte, California University of California, Los Angeles (UCLA), Los Angeles, California Sarah Cannon Research Institute at HealthOne, Denver, Colorado Sibley Memorial Hospital, Washington D.C., District of Columbia Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute, Orlando, Florida Emory University School of Medicine, Atlanta, Georgia Community Health Network, Indianapolis, Indiana Massachusetts General Hospital, Boston, Massachusetts Dana-Farber Cancer Institute, Boston, Massachusetts Barbara Ann Karmanos Cancer Institute, Detroit, Michigan South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan New York University (NYU) Langone Medical Center, New York, New York David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York Duke University Medical Center, Durham, North Carolina University of Cincinnati (UC) - Cancer Institute, Cincinnati, Ohio Cleveland Clinic, Cleveland, Ohio University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center, Pittsburgh, Pennsylvania Sarah Cannon Research Institute, Nashville, Tennessee USO - US Oncology Research Network, Nashville, Tennessee Vanderbilt University School of Medicine, Nashville, Tennessee MD Anderson Cancer Center, Houston, Texas South Texas Accelerated Research Therapeutics (START), San Antonio, Texas Huntsman Cancer Institute, Salt Lake City, Utah Fred Hutchinson Cancer Center, Seattle, Washington University of Wisconsin - Carbone Cancer Center, Madison, Wisconsin Canada
The Ottawa Hospital, Ottawa Princess Margaret Hospital, Toronto China
Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing Beijing Cancer hospital, Beijing Harbin Medical University Cancer Hospita, Harbin Fudan University Cancer Center, Shanghai France
Centre d'Essais Precoces en Cancerologie de Marseille (CEPCM) - AP-HM Hopital de La Timone, Marseille Oncopole Claudius Regaud, Toulouse Institut Gustave Roussy, Villejuif Germany
Charite Universitaetsmedizin Berlin, Berlin Universitaetsklinikum Carl Gustav Carus Dresden, Dresden Universitaetsklinikum Essen, Essen Klinikum der Ludwig-Maximilians-Universitaet Muenchen, München Ireland
START Dublin Early Phase Clinical Trials Unit, Dublin Italy
Azienda Ospedaliera Universitaria - Universita degli Studi della Campania Luigi Vanvitelli, Naples UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Roma Centro Ricerche Cliniche di Verona s.r.l., Verona Japan
National Cancer Center Hospital East, Chiba Kanagawa cancer center, Kanagawa Aichi Cancer Center Hospital, Nagoya Kansai Medical University Hospital, Osaka National Cancer Center Hospital, Tokyo Spain
South Texas Accelerated Research Therapeutics (START) Barcelona- HM Nou Delfos, Barcelona Hospital Universitario Vall d'Hebron, Barcelona South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz, Madrid Hospital Universitario 12 de Octubre, Madrid